GSK reports positive phase 1b data for lung cancer drug candidate
GSK (LSE/NYSE:GSK) reported positive phase 1b trial data for risvutatug rezetecan, a lung cancer drug candidate, showing a 61% response rate at 8 mg/kg dose. The trial involved 50 patients with relapsed extensive-stage small cell lung cancer. GSK plans to proceed with a global phase III study using the 8 mg/kg dose. The company acquired rights to the drug from Hansoh Pharma, excluding certain regions.
How this was made
The 30-second read
Why it matters
The 61% response rate at the 8 mg/kg dose markedly exceeds the 32% at 6 mg/kg, supporting dose selection for the pivotal trial and potentially boosting investor confidence.
Market read
First‑report positive Phase 1b data for a late‑stage oncology candidate, likely to influence GSK's valuation and sector sentiment.
What to watch
The data excludes China, Hong Kong, Macau and Taiwan markets where the drug rights are not held by GSK.
Background
GSK acquired worldwide rights to the ADC from Hansoh Pharma and is advancing it through Phase III trials for small‑cell lung cancer and prostate cancer.
Ticker impact
GSK reported positive Phase 1b data for its lung cancer ADC risvutatug rezetecan, showing a 61% response rate at the 8 mg/kg dose.
upward pressure as the market prices in the encouraging efficacy results
Phase 1b data is a primary disclosure with material clinical significance; such news typically triggers buying interest in the biotech segment.
Market effects
Strengthens the oncology/biotech sector outlook, especially for ADC platforms.
Positive for European pharma stocks, with modest spill‑over to US biotech indices.
Adds confidence to the broader pipeline of antibody‑drug conjugates worldwide.
Counterpoint
Investors may question the safety profile, noting 42% grade 3+ adverse events at the higher dose.
Key entities
- companyGSK plc
British pharmaceutical giant reporting the trial data.
- companyHansoh Pharma
Original developer of the ADC, rights sold to GSK outside Greater China.
